Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein, Inc. reports developments across its health care distribution, practice solutions, and dental technology businesses. The company serves office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites through business, clinical, technology, and supply chain solutions.
Recurring news themes include earnings releases, financial guidance, investor conference participation, board and executive governance updates, and product announcements from Henry Schein One. Recent technology coverage centers on Dentrix Ascend, a cloud-based dental platform that integrates practice management, clinical workflows, imaging, revenue cycle management, analytics, patient experience tools, and AI-enabled workflow capabilities.
Henry Schein (NASDAQ:HSIC) will present at two investor conferences in Miami in March. Presentations are scheduled for March 9, 2026 at 10:00 a.m. ET and March 10, 2026 at 10:30 a.m. ET, with live webcasts and subsequent replays available on the company website.
Investors can access live audio via the Henry Schein investor webcast page; replays will be posted after each presentation.
Henry Schein (Nasdaq: HSIC) reported Q4 2025 net sales of $3.4 billion, up 7.7% year-over-year, driven by equipment, specialty products and technology. GAAP diluted EPS was $0.85 and non-GAAP diluted EPS was $1.34 for Q4. Full-year 2025 sales were $13.2 billion (+4.0%).
Management announced 2026 guidance of non-GAAP diluted EPS $5.23–$5.37 and total sales growth ~3–5%, and reported $850 million of share repurchases in 2025 with $780 million available.
Henry Schein One (NASDAQ:HSIC) launched Image Verify, an AI-enabled image quality tool natively embedded in Dentrix and Dentrix Ascend to assess clinical images in real time at capture.
The company says Image Verify flags blur, misalignment, and incomplete coverage to prevent documentation-related denials; Dentrix customers also receive a new Claims Manager this month.
Henry Schein One (NYSE:HSIC) announced a direct integration connecting Align Technology’s iTero intraoral scanners with Dentrix, Dentrix Ascend, and Dentally, enabling automatic import of scans into patient records and eliminating manual uploads.
The integration, built with Align Technology and piloted with Heartland Dental, aims to streamline diagnosis, treatment planning, and practice workflows and is available to eligible customers in North America and select international markets.
Henry Schein (Nasdaq: HSIC) is a longtime national sponsor of the American Dental Association Foundation’s Give Kids A Smile (GKAS) program, which has reached more than 10.2 million children since 2003. The 2026 effort aims to deliver services to an estimated 325,000 children via 1,200 events and 23,000 volunteers.
Henry Schein has contributed over $20 million in products to GKAS and prepared more than 2,600 dental kits for volunteers in 2026, reinforcing the company’s charitable and community health commitments.
Henry Schein (Nasdaq: HSIC) will release its fourth quarter 2025 financial results before the market opens on Tuesday, February 24, 2026.
The company will host a live webcast of its earnings conference call the same day beginning at 8:00 a.m. Eastern. Speakers include Stanley M. Bergman, chairman and CEO, and Ronald N. South, SVP and CFO. Investors can access the live call and a replay via the company's investor webcasts page.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Henry Schein (HSIC) will present at the J.P. Morgan Healthcare Investor Conference on Tuesday, January 13, 2026 at 3:00 p.m. PST / 6:00 p.m. EST at The Westin St. Francis in San Francisco.
Presentations will be available live via webcast at www.henryschein.com/IRwebcasts, with replays posted on the Henry Schein investor website after the event. The company provides health care solutions to office-based dental and medical practitioners.
Henry Schein (Nasdaq: HSIC) said its board expects to appoint the company's next CEO by mid-January 2026. The board described the search as nearing completion after evaluating a pool of highly qualified candidates with exceptional interest and caliber. The company confirmed the decision will not be finalized before year-end and that Stanley Bergman will continue as CEO & Chairman at the board’s request until a successor assumes the role.
The announcement frames a targeted timeline for leadership transition while emphasizing continuity of operations and a planned, orderly handover.
Henry Schein (Nasdaq: HSIC) expanded its agreement with vVARDIS to become the exclusive U.S. distributor of Curodont™ Repair Fluoride Plus across all dental market segments, effective January 1, 2026.
The expanded deal broadens prior 2024 exclusivity for Dental Service Organizations to include general dentistry, orthodontics, and pediatric dentistry nationwide. vVARDIS founders report having accessed over 10% of U.S. dental offices and treated more than 500,000 patients with Curodont. Henry Schein is currently the market leader selling Curodont to general practitioners and DSOs in the U.S. The product offers a drill- and needle-free treatment for early-stage cavities, which the companies describe as an opportunity to increase in-office care for untreated early lesions.